Skip to main content
OpenTrials
Completed

NCT Number: NCT02001779

IRS(Irradiation Stent) vs. CS(Conventional Stent) Insertion in Inoperable Malignant Biliary Obstruction

Stenting the malignant biliary obstruction is considered to be the preferred palliation modality to relieve pruritus,cholangitis,pain and jaundice in patients without surgical indications of malignant biliary obstruction.An unicentral clinical trial has demonstrated the safety and technical feasibility of an irradiation biliary stent insertion in patients with biliary obstruction caused by adenocarcinomas, such a treatment seems have benefits in relieving jaundice and extending survival when compared to a conventional biliary stent.However,the small sample size,the population distribution of two groups will influence the final results in obtaining a powerful statistical conclusion.Therefore,a multicentric study was designed to prospectively compared the responses to the treatment with this irradiation biliary stent versus the conventional biliary self-expandable stent in patients with inoperable malignant biliary obstruction.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Zhongda Hospital,Southeast University

Nanjing, Jiangsu, 210009, China

About this study

Malignant biliary obstruction is a common condition caused by various carcinomas.The clinical process is usually silent and insidious,only 10-20% patients can be surgically removed once obstructive jaundice occurred.The long-term survival rate after resection remain dismal.Relief of obstructive jaundice plays major role on prognosis in patients without surgical indications.For unresectable patients,stenting the biliary obstruction is considered to be the preferred palliation modality to relieve pruritus,cholangitis,pain and jaundice.Although a number of new techniques for treatment of malignant biliary obstruction have been developed,there have been no significant differences in survival or quality of life comparing surgery bypass versus plastic stent insertion,metal stent insertion versus plastic stents insertion,or covered stent versus uncovered stents insertion in such patients.Our previous unicentric clinical trial has demonstrated the safety and technical feasibility of a biliary intraluminal irradiation stent insertion in patients with biliary obstruction caused by adenocarcinomas, such a treatment seems have benefits in relieving jaundice and extending survival when compared to a conventional biliary stent.However,the small sample size,the population distribution of two groups will influence the final results in obtaining a powerful statistical conclusion in the overall survival and stent patency between two groups.Therefore,a multicentric study was designed to prospectively compared the responses to the treatment with this irradiation biliary stent versus the conventional biliary self-expandable stent in patients with inoperable malignant biliary obstruction.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical,histological or pathological diagnosis of malignant biliary obstruction
  • Unresectability or refusal to be surgically treated
  • The Eastern Cooperative Oncology Group(ECOG) scores from 0 to 3
  • With symptoms such as jaundice related to biliary obstruction
  • Willing and able to comply with the study procedures and provide written informed consent to participate in the study
  • Biliary obstruction of Bismuthe-Corlette,type I and II

Exclusion criteria

  • Benign biliary obstruction
  • The Eastern Cooperative Oncology Group(ECOG) score of 4
  • Biliary tract stricture that could not be dilated enough to pass the delivery system
  • Presence of metallic biliary stent or bile duct surgery
  • Percutaneous transhepatic cholangiography(PTC) procedure was contraindicated
  • Active hepatitis
  • Biliary obstruction of Bismuthe-Corlette,type Ⅲ and Ⅳ
  • Uncooperative or could not provide authorization and signature

Treatment and study plan

Biliary SEMS loaded with 125I seeds

Device

A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.

Conventional biliary SEMS

Device

A self-expandable metallic stent is inserted in patients with inoperable malignant biliary obstruction.

Primary outcomes

  1. Patency

    Time frame: Participants will be followed till die or lost to follow-up,an expected average of a year.

    Time from stenting to the day when stricture/obstruction of the stent occured or restricture/reobstruction after recanalization the obstructed stent.

Secondary outcomes

  1. Over survival

    Time frame: Participants will be followed till die or lost to follow-up,an expected average of a year.

    Time from stenting to the day when the patients died or lost to the follow-up.

  2. Clinical success

    Time frame: Participants will be followed till die or lost to follow-up,an expected average of a year.

    The rate of relief of the symptoms and signs of the patients.

  3. Safety

    Time frame: Participants will be followed till die or lost to follow-up,an expected average of a year.

    Including technique success rate,side effect/complication,radioactive safety.

Sponsors and collaborators

Lead sponsor

Zhongda Hospital

Other

Registry information

Official study title

Study of Stent Insertion Combined With or Without Brachytherapy in Patients With Inoperable Malignant Biliary Obstruction

Acronym: IRCSMBO

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Dec 5, 2013
Registry last updated
Feb 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.